This study is in progress, not accepting new patients
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- TG Therapeutics, Inc.
- ID
- NCT02793583
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 900 study participants
- Last Updated